Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc (VOR) is a clinical-stage biotechnology pioneer developing engineered hematopoietic stem cell (eHSC) therapies for hematological cancers. This page serves as the definitive source for verified corporate announcements, clinical trial updates, and strategic developments related to their innovative platform.
Investors and researchers will find timely updates on key milestones including trial progress, regulatory filings, and partnership announcements. All content is curated to provide actionable insights into the company’s novel approach to protecting healthy cells during cancer treatments while enabling targeted tumor eradication.
The resource features press releases covering financial results, manufacturing advancements, and peer-reviewed research publications. Scientific updates detail progress in their eHSC platform’s applications for CAR-T therapies and antigen-targeted treatment regimens.
Bookmark this page for streamlined access to Vor Biopharma’s latest developments in cell engineering and hematological oncology research. Regularly updated to reflect new data presentations, clinical collaborations, and pipeline expansions.
Vor Bio (Nasdaq: VOR) announced the appointment of Jeremy Sokolove, M.D. as Chief Medical Officer effective Nov 3, 2025. Dr. Sokolove brings more than two decades of clinical and translational experience in rheumatology and autoimmune disease research and development.
His recent roles include Chief Medical Officer In-Residence at Roivant Sciences, Chief Medical Officer at Odyssey Therapeutics, Senior VP and Head of Clinical Pharmacology at GSK, and Head of Immunology Translational Science at AbbVie. He began his career on the faculty at Stanford and holds an MD from Boston University School of Medicine.
The company says Dr. Sokolove will drive clinical strategy and lead the global development program for Telitacicept, targeting BAFF/APRIL pathways to address autoimmune diseases.
Vor Bio (Nasdaq: VOR) announced that on October 15, 2025 its Compensation Committee granted inducement awards to 20 newly hired employees under the Vor Biopharma 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards comprise 113,478 stock options and 24,319 RSUs. Options have a 10-year term with an exercise price of $30.22 (closing price on grant date). Options vest over four years (25% after 12 months, then monthly over 36 months). RSUs vest over four years (25% after 12 months, then quarterly over 36 months). Awards are subject to the Inducement Plan and individual award agreements.
Vor Bio (Nasdaq: VOR) collaborator RemeGen presented 48-week open-label extension data for telitacicept in generalized myasthenia gravis on Oct 29, 2025.
Key efficacy: continuous-treatment patients had a mean -7.5 MG-ADL change and crossover patients -6.3 at week 48; continuous patients had mean -9.8 QMG change and crossover -9.3. 96.2% of continuous and 90.2% of crossover patients reached ≥3-point MG-ADL improvement; most adverse events were mild‑to‑moderate with no new safety signals.
Vor Bio (Nasdaq: VOR) will host a live webcast to present newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease.
The study was conducted by collaborator RemeGen. Vor Bio management and Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results.
Webcast: Tuesday, October 28, 2025 at 4:30 PM Eastern Time. Registration options include listen-only and listen-with-live Q&A links; a replay will be posted at https://ir.vorbio.com/events-presentations/ approximately two hours after the call and will remain available for 30 days.
Vor Bio (Nasdaq: VOR) said clinical data from Stage A of a China Phase 3 study of telitacicept in adults with IgA nephropathy (IgAN) will be a late-breaking oral presentation at ASN Kidney Week 2025 on Nov 8, 2025 at 10:45 AM CT.
Topline results reported a 55% reduction in 24-hour urine protein-to-creatinine ratio (UPCR) at 39 weeks versus placebo (p<0.0001) and a favorable safety profile. RemeGen has submitted a BLA to China’s CDE/NMPA for IgAN; approval would be telitacicept’s fifth indication in China.
Vor Bio (Nasdaq: VOR) announced publication in The New England Journal of Medicine of a China Phase 3 trial of telitacicept in systemic lupus erythematosus (SLE).
The randomized 335-patient study across 42 hospitals met its primary endpoint at week 52: 67.1% response for telitacicept versus 32.7% for placebo (P<0.001). Key secondary results: SELENA-SLEDAI ≥4 point reduction in 70.1% vs 40.5%; mean SELENA-SLEDAI change -4.95 vs -1.0; median time to flare 198 vs 115 days; steroid reduction in 44.9% vs 34.7%; kidney proteinuria improvements 71.8% vs 55.1%. Safety: more URTI (31.7% vs 19.0%) and injection-site reactions (12.6% vs 0.6%); serious adverse events were lower (7.2% vs 14.3%).
Vor Bio (NASDAQ: VOR) announced positive 48-week China Phase 3 results for telitacicept in primary Sjögren’s disease, presented at ACR Convergence 2025 on October 28, 2025. The 160mg dose met the primary endpoint (change in ESSDAI at week 24) and all secondary endpoints with p<0.0001 versus placebo, showing durable benefit through 48 weeks.
Key metrics: 71.8% of patients on 160mg achieved ≥3-point ESSDAI reduction at week 24 vs 19.3% placebo; mean ESSDAI change at week 24 was -4.4 (160mg) vs -0.6 (placebo). Safety was comparable to placebo with no new signals.
Vor Bio (Nasdaq: VOR) announced on Oct 3, 2025 that on Sept 19, 2025 its Compensation Committee granted inducement awards to eight newly hired employees under the 2023 Inducement Plan.
The grants consist of 76,360 stock options (10‑year term) and 16,361 RSUs. The option exercise price is $30.40 per share (closing price on grant date). Options vest over four years (25% after 12 months, then monthly over 36 months); RSUs vest over four years (25% after 12 months, then quarterly over 36 months). Awards are subject to plan and award agreement terms and continued employment.
Vor Bio (NASDAQ:VOR) announced that clinical data from their Phase 3 study of telitacicept in primary Sjögren's disease will be presented at ACR Convergence 2025 (October 24-29, 2025) in Chicago. The study, conducted in collaboration with RemeGen Co., Ltd, will be featured as a late-breaking poster presentation.
Notably, RemeGen has already submitted a Biologics License Application (BLA) to China's National Medical Products Administration for telitacicept in primary Sjögren's disease. If approved, this will mark telitacicept's fourth approved indication in China.
Vor Bio (Nasdaq: VOR) has appointed Dr. Navid Z. Khan as Chief Medical Affairs Officer. With over 20 years of experience, Dr. Khan brings extensive expertise in medical affairs, commercial operations, and R&D. He has overseen 40+ development programs and led seven successful product launches in rare neurology and immunology indications.
Most recently at argenx, Dr. Khan headed the Neuromuscular Therapeutic Area, Medical Affairs, where he led four launches of VYVGART® products. His previous roles include leadership positions at Akouos Inc. and Sarepta Therapeutics, where he was instrumental in launching three Duchenne muscular dystrophy therapies and preparing the company's Medical Affairs organization for gene therapy programs.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
